论文部分内容阅读
目的:探讨复方嗜酸乳杆菌片联合四联疗法治疗幽门螺杆菌(Hp)阳性的消化性溃疡患者的临床疗效与安全性。方法:112例Hp阳性的消化性溃疡患者随机分为对照组和观察组各56例。对照组使用四联疗法根除Hp,然后予以奥美拉唑抑酸治疗,观察组在对照组基础上加用复方嗜酸乳杆菌片进行治疗。观察两组患者临床疗效、Hp根除率及药物不良反应发生情况。结果:两组治疗后临床症状积分均明显低于治疗前(P<0.01),且观察组积分降低更显著(P<0.01);观察组与对照组总有效率分别为94.6%和78.6%,ADR发生率分别为3.6%和17.9%,两组间差异均有统计学意义(P<0.05),Hp根除率分别为92.9%和80.4%,两组间差异无统计学意义(P>0.05)。结论:复方嗜酸乳杆菌片联合四联疗法治疗Hp阳性的消化性溃疡疗效显著,不良反应少。
Objective: To investigate the clinical efficacy and safety of compound acidophilus Lactobacillus tablets combined with quadruple therapy in the treatment of patients with Helicobacter pylori (Hp) -positive peptic ulcer. Methods: One hundred and twelve patients with Hp-positive peptic ulcer were randomly divided into control group and observation group of 56 cases. The control group was treated with quadruple therapy to eradicate Hp, followed by omeprazole acid suppression therapy. The observation group was treated with Compound Lactobacillus acidophilus on the basis of the control group. The clinical efficacy, Hp eradication rate and adverse drug reactions in both groups were observed. Results: The scores of clinical symptoms in both groups were significantly lower than those before treatment (P <0.01), and the scores in the observation group decreased more significantly (P <0.01). The total effective rates in the observation group and the control group were 94.6% and 78.6% The incidences of ADR were 3.6% and 17.9% respectively, with significant difference between the two groups (P <0.05). The eradication rates of Hp were 92.9% and 80.4% respectively, with no significant difference between the two groups (P> 0.05) . Conclusion: Lactobacillus acidophilus combined with quadruple therapy for Hp-positive peptic ulcer has significant curative effect and few adverse reactions.